ASSEMBLY BIOSCIENCES, INC. — Director's Dealing 2023

Mar 31, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ASSEMBLY BIOSCIENCES, INC. (ASMB)
CIK: 0001426800
Period of Report: 2023-03-29

Reporting Person: Okazaki Jason A (Director, CEO and President)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-03-30	Common Stock	S	4247	$0.8232	Disposed	98174	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2023-03-29	Stock Option (right to buy)	$0.89	A	470000	Acquired	2033-03-29	Common Stock (470000)	Direct

Footnotes

F1: The sale reported on this Form 4 represents shares sold by the reporting person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units ("RSUs"). The sale is mandated by an administrative rule adopted by the Compensation Committee of the Issuer's Board of Directors that requires the satisfaction of tax withholding obligations to be funded by a "sell-to-cover" transaction and does not represent a discretionary transaction by the reporting person.

F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.7795 to $0.89, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within.

F3: Grant of stock options. The stock options vest over four years, assuming continuous service on each vesting date, as follows: 25% vest on the first anniversary of the date of grant, March 29, 2024; and the remaining 75% vest in 36 approximately equal monthly installments, with the options becoming fully vested on March 29, 2027.